STAGE III DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8
Clinical trials for STAGE III DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat thyroid cancer: drug XL092 enters human trials
Disease control Recruiting nowThis phase 2 trial tests a drug called XL092 in 33 people with advanced thyroid cancer that has stopped responding to radioiodine therapy. XL092 works by blocking a protein that helps cancer cells grow. The study aims to see if the drug can slow or stop cancer progression.
Matched conditions: STAGE III DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Jochen Lorch • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Friends and fitness: key to life after cancer?
Knowledge-focused Recruiting nowThis study follows 250 young adult cancer survivors to see how their social relationships and physical activity change over time and how these factors affect their quality of life. Participants wear an activity tracker and complete surveys. The goal is to learn how to better supp…
Matched conditions: STAGE III DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8
Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC